Clinical Trials Browser

Phase 3 × Has announcements × gilteritinib × Clear all

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

371 enrolled 36 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute